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Abstract: 
Recent years have seen important advances in our understanding of the 
etiology, biology and genetics of kidney cancer, some of which have been 
accompanied by impressive clinical advances. While these have occurred at 
a time when the incidence of kidney cancer among adults continues to 
increase in North America and most parts of Europe, elsewhere globally, 
rates remain stable. In order to summarize important achievements and 
identify prominent research questions that remain for kidney cancer, a 
workshop was organized by the International Agency for Research on 
Cancer (IARC) and the US National Cancer Institute (NCI) in the Spring of 
2015. Based on a review of major themes in population, genomic and 
clinical research, a series of ‘difficult questions’ were formulated, which 
should be given future priority within each of these areas.   
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Introduction (131) 
 
Recent years have seen important advances in our understanding of the etiology, biology and 
genetics of kidney cancer, some of which have been accompanied by impressive clinical 
advances. While these have occurred at a time when the incidence of kidney cancer among 
adults continues to increase in North America and most parts of Europe, elsewhere globally, 
rates remain stable. In order to summarize important achievements and identify prominent 
research questions that remain for kidney cancer, a workshop was organized by the 
International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) 
in the Spring of 2015. Based on a review of major themes in population, genomic and clinical 
research, a series of ‘difficult questions’ were formulated, which should be given future priority 
within each of these areas.   
 
 
Overview (1055): 
 
Worldwide, it is estimated that there are over 300,000 new cases of kidney cancer per year. 
Rates are generally lower in most parts of Asia and Latin America when compared to Europe 
and North America.1 In the United States, kidney cancer incidence varies across distinct 
populations, with rates highest among African Americans and lowest among Asian Americans. 
In Europe, a particularly notable feature is the strikingly high rate observed in the Czech 
Republic, with elevated rates observed in surrounding regions including Slovakia, the Baltic 
countries, eastern Germany and Northern Italy,2 yet there is no evident explanation to account 
for this geographic pattern. There is also a consistent male to female excess of kidney cancer 
observed in both low and high incidence regions that is similarly not explained. Understanding 
these basic epidemiologic patterns of kidney cancer across the world could lead to insights into 
the biological mechanisms that contribute to this malignancy. Genetics and differences in 
detection of asymptomatic cases from diagnostic imaging could partially explain these 
geographic and ethnic discrepancies, although it is also likely that exposures and lifestyle 
choices contribute. The main established risk factors of kidney cancer are elevated body-mass 
index (BMI), hypertension, and tobacco use,3 which have moderate estimated effects.  
 
Kidney cancer includes a spectrum of pathologies that can vary substantively, both with respect 
to rare inherited and sporadic forms, although clear cell renal cell carcinoma (ccRCC) is the 
most common. Family and population-based studies have successfully identified key 
components of the underlying genetic architecture of susceptibility to kidney cancer. Family 
studies have uncovered a series of rare but highly penetrant mutations, such as in the VHL 
gene, which not only have proven to be useful for screening and counseling in families laden 
with kidney cancer across generations but also for highlighting the importance of the VHL 
pathway in sporadic ccRCC.4 Other rare syndromes have revealed important insights into 
additional key genes for different kidney cancer subtypes and together have emerged as a 
panel for testing in kidney cancer family screening.5 Using genome-wide association studies, it 
has been possible to detect a fraction of the common variants conferring susceptibility to kidney 
cancer; these possess smaller estimated effects and tend to fall in regulatory regions that have 
an impact on redundant, key pathways related to kidney cancer development.6-9 Building on the 
knowledge of rare mutations and common variants, it is now possible to begin to build a 
polygenic risk model that will predict the familial risk for family members of a newly diagnosed 
case.  
 
The application of new genomic technologies to investigate the spectrum of somatic alterations 
in kidney cancer has led to new insights into a series of events, which could lead to new 
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therapeutics and possibly earlier detection of kidney cancer. Large-scale sequence analyses of 
sets of adult and pediatric kidney cancers have provided a view of the landscape of the more 
common types of events across the genome.10-22 Adult kidney cancers harbor large numbers of 
somatic mutations of all classes, from point mutations to structural alterations, whereas in 
pediatric kidney cancers (e.g., Wilms tumor and at least half a dozen rarer types), there are 
fewer somatic events and in fact, few instances in which a driver mutation has been identified. 
Loss of the 3p chromosomal arm, which harbors the VHL gene, is commonly observed in 
ccRCC, underscoring the importance of the VHL network and its effect on key metabolic 
pathways in kidney carcinogenesis. VHL alteration also is the likely reason that VEGF pathway 
directed anti-angiogenic strategies have shown some success. New drivers of kidney cancer 
have been identified, partly on the basis of the frequency of mutations in key genes, and partly 
on the basis of corroborative laboratory work.23   
 
Characterization of rarer types of kidney cancer has led to new insights, in some instances 
providing opportunities to understand how germline mutations inform an understanding of the 
somatic alterations. Similarly, initial studies have revealed the importance of the dynamic 
genome, known as the epigenome in both adult and in particular, pediatric subtypes of kidney 
cancer.24 In this regard, the microenvironment has emerged as a critical focus for ongoing 
research in order to understand how and in what way the ongoing interaction between host 
factors and developing tumors either accelerates or inhibits tumor formation.   
 
An important characteristic of kidney carcinogenesis is the role of alterations in metabolic 
pathways, beginning with the VHL network25. Germline genetic susceptibility (e.g., both common 
variants and highly penetrant familial mutations) have pointed towards VHL and associated 
genes, such as EPAS1. Metabolic disruption can directly contribute to kidney cancer 
development, both in genomic studies and in laboratory investigations of models, tissue culture 
and tumor tissue studies. In parallel with these seminal discoveries has been a strong interest in 
characterizing the role of an elevated BMI, perhaps through a range of metabolic syndromes or 
disruptions.   
 
The discovery of stable and reproducible biomarkers for risk or earlier diagnosis of kidney 
cancer using germline genetics or serum/urinary biomarkers remains a daunting challenge. 
Many small studies have provided preliminary observations but in larger data sets, the utility of 
candidate or pathway analyses remains elusive. Such molecular epidemiologic studies could 
provide insight into mechanisms of kidney cancer and improve prediction models. Our capacity 
to achieve these goals will be based on increasing the scope of our understanding of mutations 
and biomarkers applied to substantively larger investigations, preferably using prospectively 
collected biospecimens in order to identify markers of risk.  
 
Therapeutic approaches to kidney cancer have blossomed in the last decade, fueled by new 
targeted therapies (e.g., designer drugs that attack specific proteins or pathways critical for 
angiogenesis and immune regulation). There are more than half a dozen new targeted agents in 
use for metastatic cases, many showing impressive initial responses, but resistance is invariably 
observed which limits the ability to impact long-term survival.26 Proteomic and circulating 
biomarker studies have provided promising leads for understanding determinants of tumor 
progression and metastases, a major problem in kidney cancer. Immunotherapy for kidney 
cancer has progressed from cytokine based therapies to PD-1 and PDL-1 blockade. Many 
exciting reports have detailed successful applications of immunotherapy, with a recent phase 3 
trial showing longer survival in patients receiving this new treatment.27 More studies will be 
needed to advance this exciting component of precision medicine, particularly as it relates to 
selection of patients with a high probability of response to therapy.   
Page 4 of 9Annals of Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Future directions (929): 
 
The exciting trends in molecular characterization and targeted therapy of kidney cancer should 
be matched with a new commitment to understanding the etiology and pathogenesis of this 
malignancy. How and why there are major differences by sex, race, geography and exposure 
histories underscores the complexity of kidney cancer etiology. Global assessment of incidence 
but also outcomes of therapeutic approaches could reveal important observations that, in turn 
could inform both the underlying biology and identify new targets for early detection or therapy. 
The shift towards molecular characterization of adult and pediatric cancers has uncovered a 
series of important questions related to the key pathways underlying the spectrum of kidney 
cancer. Heterogeneity in somatic changes has emerged as a significant challenge in kidney 
cancer, revealing that distinct cancers within an individual may have to be targeted in parallel, 
unless there is an Achilles’ heel that can be targeted upstream.28 Moreover, the analysis of 
somatic signatures could reveal important clues to environmental and lifestyle factors that 
contribute to kidney cancer.16,29  
 
Over the past two decades, the detection of germline susceptibility alleles, both common and 
rare, has accelerated our understanding of the underlying genetic architecture of how kidney 
cancer develops. The new tools of genome-wide association and next generation sequencing 
studies should continue to be applied to progressively larger and better-annotated data sets to 
further add to the comprehensive catalog of susceptibility alleles. The utility of screening 
subsets of newly diagnosed cases of kidney cancers has already emerged as a compelling 
argument and merits further investigation, particularly in families or outliers (such as younger 
cases of ccRCC or the spectrum of rare subtypes). Similar commitment to the genetics of 
pediatric forms of kidney cancer could be useful for future screening approaches, especially in 
high-risk settings. Special attention should be given to conducting these studies in populations 
with different genetic histories and exposures. The ability to examine gene-environment 
interactions either directly or through the approach of Mendelian randomization should be a high 
priority for discovery of new relationships, some of which could be harnessed for detection or 
prevention.30  
 
Further characterization of the genomic landscape of kidney cancers, including larger numbers 
of rarer cancers, should provide an important foundation for identifying the catalog of driver 
events. While The Cancer Genome Atlas (TCGA) and International Cancer Genome 
Consortium (ICGC) have provided an impetus to conduct large scale characterization projects, 
the international community should develop a shared data resource to combine academic, 
clinical and research resources to rapidly accelerate the bioinformatics analyses of the spectrum 
of kidney cancer. So far, the number of samples studied has led to the identification of genes 
that are commonly mutated. As kidney cancer has emerged as one of the pivotal examples of 
tumor heterogeneity, together with its spectrum of rare and common subtypes, many more 
tumor/normal pairs will require characterization in order to capture key events, both for targets 
and prognostic factors.31 The next generation of genomic characterization efforts should be 
conducted in studies that have collected both epidemiologic risk factors, including pre-diagnostic 
biomarkers when possible, and extensive annotation of the clinical parameters including long-
term outcome. The investigation of somatic alterations with clinical outcomes should be a high 
priority, including detailed analyses of tumor heterogeneity, which might require regional 
sampling guided by imaging. The challenge of heterogeneity has important implications for 
therapeutic decisions, and perhaps in the future therapeutic monitoring, especially if circulating 
tumor DNA or tumor cells can be adapted as an efficient and widespread technique. Current 
approaches to develop models for the evolution of kidney cancer represent an important parallel 
approach, one that should be iteratively coordinated with clinical characterization of the cancer 
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genome and its epigenomic changes.28 Serial and regional biopsies in well-characterized 
biorepositories should be available and include detailed follow-up on outcomes, therapeutic 
interventions and new imaging techniques. A critical question of the future will be how and in 
what way imaging-based techniques can be harmonized with genomic technologies to identify 
targets, but equally new target identification will need to be combined with the parallel 
development of predictive genomic and proteomic biomarkers to enable patient stratification.  
 
The rapid acceleration of immune-based therapies should remain a major focus of kidney 
cancer research, providing new insights into how and in what way the immune system could 
better conduct surveillance against emerging cancers and to treat kidney cancer. The collective 
assessment of the different strategies could shed light on prognostic factors, such as the HLA 
haplotypes and circulating biomarkers. Eventually, the use of immunotherapy may be a central 
component in the armamentarium of precision medicine tools. Determinants of immune-based 
therapeutic success should provide new insights into stratification of individual patients, perhaps 
based on emerging immune profiles of both measured biomarkers and genetic predisposition.   
 
In conclusion, the tools of genomic characterization and targeted therapy have begun to 
accelerate the investigation of the basic biology of kidney cancer, thus providing novel 
approaches towards improving early detection, intervention and monitoring of kidney cancer. 
The development of a more refined molecular taxonomy of the spectrum of kidney cancer will 
advance most efficiently if the community continues to develop more robust approaches to data 
sharing. Interoperability between data resources should remain a central goal both for resources 
generated by “-omic” technologies and more precise phenotyping, based on sound 
epidemiologic and clinical practice. By integrating data sets, the opportunity to determine shared 
and unique features should benefit the diagnosis, treatment and monitoring of rare and common 
kidney cancers alike. In the distant future, it may emerge that precision prevention strategies are 
possible, but they will be based on further research in all corners of the globe.  
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One dozen difficult questions that should be prioritized: 
1 
What is the explanation for the geographical, racial/ethnic and sex differences 
in the incidence of kidney cancer? 
2 
What underlying biologic pathways drive the association between 
obesity/hypertension, and kidney cancer risk? 
3 
Can a greater understanding of germline variation of kidney cancer inform us 
about the unknown lifestyle and environmental causes? 
4 
Can a better understanding of the somatic signatures (both genomic and 
proteomic) of kidney cancer and its subtypes provide clues to etiologic risk 
factors and prognosis? 
5 
How is response to targeted therapy and immunotherapy influenced by 
epigenetic variation? 
6 
With more than a half a dozen approved drugs targeting the VHL/HIF pathway 
in clear cell renal cell carcinomas, what are the next steps towards improving 
therapy and survival in both early and advanced cases? 
7 
What are the barriers for rapid data sharing of sequencing of kidney cancers, 
which could accelerate identification and characterization of drivers of 
oncogenesis? 
8 
How do we select kidney cancer patients for constitutional genetic testing, 
beyond those fitting a ‘classic’ kidney cancer susceptibility syndrome? 
9 
Why do more than half of pediatric Wilms tumors lack identifiable driver 
mutations and what does this suggest about epigenetic regulation? 
10 
What new data are critical to develop more accurate models for understanding 
genomic and epigenetic changes across the spectrum of renal cancers? 
11 Are current pathological subtype classifications still clinically relevant? 
12 What factors can reliably predict durable response to immunotherapy? 
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